<unk>  has been treated as a drug with a high safety and tolerability profile. Information is scarce about<unk> 's effect on mortality, cardiovascular events, or quality of life. Long-term, randomized, controlled trials comparing<unk>  against standard antianginal agents, using clinically important outcomes would be justifiable. Recently, an international multicentre retrospective cohort study has indeed shown that in patients with heart failure of different etiologies, the addition of<unk>  on conventional optimal therapy can improve mortality and morbidity. The EMA recommends that doctors should no longer prescribe<unk>  for the treatment of patients with tinnitus, vertigo, or disturbances in vision. The recent EMA evaluation also revealed rare cases (3.6/1 000 000 patient years) of parkinsonian (or extrapyramidal) symptoms (such as tremor, rigidity, akinesia, hypertonia), gait instability, restless leg syndrome, and other related movement disorders; most patients recovered within 4 months after treatment discontinuation, so doctors are advised not to prescribe the medicine either to patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders, or to patients with severe renal impairment.
Trimetazidine
Esketamine
Eptazocine
Pentazocine
Etomidate
Bremazocine
Triethylenetetramine
Fentanyl